Lv64
2464 积分 2024-06-03 加入
Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease
10天前
已完结
Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves’ orbitopathy: a systematic review and meta-analysis
10天前
已完结
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease
10天前
已完结
Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease
10天前
已完结
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
10天前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
10天前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
17天前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
17天前
已完结
Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia
18天前
已完结
皖公网安备34019202002308
